The effect of Royal Jelly supplementation on inflammation, androgenic hormone status, and clinical symptoms in women with polycystic ovary syndrome: A randomized clinical trial study

Articles in Press

Document Type : Original Article (s)

Authors

Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

10.48305/jims.2025.45288.2484

Abstract

Background: As the endocrine and metabolic disorder of women of reproductive age, Polycystic ovarian syndrome (PCOS) is common, with a multifaceted etiology.(1) Insulin dysfunction and hyperandrogenemia are the suggested etiologies. Recent evidence suggests that Royal Jelly (RJ) has anti-androgenic and glucose hemostasis effects in PCOS animal models.(2) This investigation aimed to evaluate the effect of RJ consumption on androgenic hormones, glycemic, inflammatory indices, and clinical signs of women with PCOCS.
Methods: The present clinical trial was conducted on 22 women with PCOS who received either RJ (1000mg/day) or placebo (1000mg/day) for 8 weeks. Study endpoints were evaluating the androgenic hormones, glucose-related parameters, IL-6, CRP, and clinical signs of PCOS, pre-and post-intervention.
Findings:
RJ supplementation gave rise to a marked decrement of serum testosterone in the RJ group after adjustment for the confounders (P< 0.001). A significant decrease in levels of CRP was noticed in the intervention arm, relative to placebo at the end of the study following potential confounding factors adjustments (Model 1 P=0.035, model2 P=0.003). Regarding clinical signs, there was an improvement in oligomenorrhea and acne severity following RJ supplementation in the PCOS group (P<0.001, P=0.022 respectively). Following RJ supplementation for eight weeks, 1 in 4 patient’s acne severity declined in PCOS patients.
Conclusion: It is suggested that RJ supplementation could remarkably ameliorate androgen hormones, inflammation, and clinical signs of patients with PCOS(3-5) More investigations with more sample sizes, extensive periods, and distinct doses are suggested.

Highlights

Naimeh Mesri Alamdari: Google Scholar, PubMed

Majid Mobasseri: Google Scholar, PubMed

Keywords

Main Subjects

Journal of Isfahan Medical School

Articles in Press, Accepted Manuscript
Available Online from 15 July 2025

Files

History

  • Receive Date: 31 May 2025
  • Accept Date: 16 June 2025

Share

How to cite

Statistics